Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug. The ...

Nuestra adopción de la tecnología ha sido tan rápida que estamos perdiendo la capacidad de darnos cuenta qué se siente vivir de esta manera. By Steven Barrie-Anthony She studied the impact of noise on ...